Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Nurix Therapeutics, Inc. (NRIX : NSDQ)
 
 • Company Description   
Nurix Therapeutics Inc.is a biopharmaceutical company. It focuses on the discovery, development and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company's product candidates include NX-2127 and NX-1607 which are in clinical stage. Nurix Therapeutics Inc.is based in San Francisco, California.

Number of Employees: 317

 
 • Price / Volume Information   
Yesterday's Closing Price: $15.79 Daily Weekly Monthly
20 Day Moving Average: 909,734 shares
Shares Outstanding: 102.84 (millions)
Market Capitalization: $1,623.89 (millions)
Beta: 1.96
52 Week High: $22.50
52 Week Low: $8.18
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -18.57% -17.96%
12 Week -8.20% -8.86%
Year To Date -16.76% -16.96%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1600 SIERRA POINT PKWY
-
BRISBANE,CA 94005
USA		 ph: 415-660-5320
fax: -		 ir@nurixtx.com http://www.nurixtx.com
 
 • General Corporate Information   
Officers
Arthur T. Sands - President and Chief Executive Officer
Julia P. Gregory - Chairman
Hans van Houte - Chief Financial Officer
Roy D. Baynes - Director
Roger Dansey - Director

Peer Information
Nurix Therapeutics, Inc. (CORR.)
Nurix Therapeutics, Inc. (RSPI)
Nurix Therapeutics, Inc. (CGXP)
Nurix Therapeutics, Inc. (BGEN)
Nurix Therapeutics, Inc. (GTBP)
Nurix Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 67080M103
SIC: 2834
Fiscal Year
Fiscal Year End: November
Last Reported Quarter: 11/01/25
Next Expected EPS Date: 04/14/26
Share - Related Items
Shares Outstanding: 102.84
Most Recent Split Date: (:1)
Beta: 1.96
Market Capitalization: $1,623.89 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.76 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-3.05 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 8.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 04/14/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.98
Price/Cash Flow: -
Price / Sales: 19.34
EPS Growth
vs. Year Ago Period: -9.33%
vs. Previous Quarter: 20.39%
Sales Growth
vs. Year Ago Period: 2.21%
vs. Previous Quarter: 71.99%
ROE
11/30/25 - -57.51
08/31/25 - -53.57
05/31/25 - -45.26
ROA
11/30/25 - -43.76
08/31/25 - -40.82
05/31/25 - -34.71
Current Ratio
11/30/25 - 7.02
08/31/25 - 5.35
05/31/25 - 6.82
Quick Ratio
11/30/25 - 7.02
08/31/25 - 5.35
05/31/25 - 6.82
Operating Margin
11/30/25 - -314.90
08/31/25 - -292.50
05/31/25 - -234.57
Net Margin
11/30/25 - -314.90
08/31/25 - -292.50
05/31/25 - -234.57
Pre-Tax Margin
11/30/25 - -314.00
08/31/25 - -291.58
05/31/25 - -233.61
Book Value
11/30/25 - 5.29
08/31/25 - 4.87
05/31/25 - 5.87
Inventory Turnover
11/30/25 - -
08/31/25 - -
05/31/25 - -
Debt-to-Equity
11/30/25 - 0.00
08/31/25 - 0.00
05/31/25 - 0.00
Debt-to-Capital
11/30/25 - 0.00
08/31/25 - 0.00
05/31/25 - 0.00
 

Powered by Zacks Investment Research ©